Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

215
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
215
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

564
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
564
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

159
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
159
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

646
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
646
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

115
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
115
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

469
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
469

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

TIME-trend and forecasting of the economic impact of inflammatory bowel disease in Catalonia: a population-based analysis.

Journal of medical economics·2026
Same author

Prevalence, incidence and mortality of pediatric inflammatory bowel disease in Catalonia (EPIBDCat).

Revista espanola de enfermedades digestivas·2026
Same author

Development and validation of the inflammatory bowel disease objective disability index (IBDODI).

Revista espanola de enfermedades digestivas·2026
Same author

Microbial signatures in psoriatic arthritis distinguish disease phenotypes and newly diagnosed inflammatory bowel disease independent of faecal calprotectin.

Annals of the rheumatic diseases·2026
Same author

Hidradenitis suppurativa in patients with inflammatory bowel disease: a national multicenter study from the GETECCU-ENEIDA Registry.

Therapeutic advances in gastroenterology·2026
Same author

Multidisciplinary spondyloarthrtis and inflammatory bowel disease unit: Report of 7 years' experience.

Reumatologia clinica·2026

相关实验视频

Updated: Jul 25, 2025

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.1K

[ 胃潰瘍 ] [ 胃潰瘍 ]

Isabel Laucirica1, Pilar García Iglesias1, Xavier Calvet2

  • 1Servei d'Aparell Digestiu, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Departament de Medicina, Universitat Autònoma de Barcelona, Sabadell, España.

Medicina clinica
|June 26, 2023
PubMed
概括

胃潰瘍病是一種常見的疾病,主要是由H. pylori感染和NSAID使用引起的. 通过内镜进行早期诊断和有效治疗,以及预防策略,对于管理这一重大健康问题至关重要.

关键词:
抗炎药没有类固醇.选择性的COX-2抑制剂胃肠道并发症是什么消化保护系统 (Gastroprotección) 是一个消化保护系统.胃口保护 胃口保护在Helicobacter Pylori的研究中,选择性的COX-2抑制剂非类固醇抗炎药物 非类固醇抗炎药物胃潰瘍疾病 胃潰瘍疾病上部胃肠道并发症 上部胃肠道并发症皮性 (Úlcera péptica) 是一种致病性.

更多相关视频

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.7K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

430

相关实验视频

Last Updated: Jul 25, 2025

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.1K
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.7K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

430

科学领域:

  • 胃肠病学 胃肠病学
  • 内部医学 内部医学

背景情况:

  • 尽管最近发病率有所下降,但胃潰瘍疾病 (PUD) 仍然是致病率和死亡率的重要原因.
  • 高昂的医疗保健费用与管理PUD相关.
  • 关键的危险因素包括Helicobacter pylori (H. pylori) 感染和非类固醇抗炎药物 (NSAID) 的使用.

研究的目的:

  • 概述了胃病的流行病学,危险因素,临床表现,诊断和管理.
  • 强调预防策略在管理PUD中的重要性.

主要方法:

  • 关于胃病的当前文献的综述.
  • 对诊断技术的分析,重点是上部胃肠道内镜.
  • 评估既定和新兴的治疗方式.

主要成果:

  • 消化不良是最常见的症状,尽管许多患者无症状.
  • 并发症包括上部胃肠道出血,穿孔和狭窄.
  • 上部胃肠道内镜是诊断的黄金标准.

结论:

  • 治疗依赖于质子抑制剂,H. pylori根除和NSAID避免.
  • 预防至关重要,包括明智的PPI使用,H. pylori管理和谨慎的NSAID选择.
  • 有效的管理需要采取多方面的方法来解决风险因素,诊断和治疗.